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LGMD2E with a novel nonsense variant 
in SGCB gene: a case of LGMD2E with a 
novel variant
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Sarcoglycanopathies are a rare group of autosomal recessive limb-girdle muscular dystrophies 
(LGMDs) caused by genetic variants in α-, β-, γ-, or δ-sarcoglycan that maintain membrane 
integrity and contribute to molecular signal processing. High-throughput nucleotide se-
quencing was performed in patients with slowly progressive proximal muscle weakness from 
early childhood with respiratory involvement, which detected a novel homozygous nonsense 
variant (c.601C>T;p.Gln201Ter) in SGCB. This report informs about the clinical characteristics of 
LGMD2E (type-2E LGMD) in Korea and provides genetic confirmation of the disease.
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Autosomal recessive limb-girdle muscular dystrophy (LGMD), which constitutes a group 
of clinically and genetically heterogeneous muscular disorders, has been linked to 
26 genes. Type-2C LGMD (LGMD2C) to LGMD2F are due to variants in the diverse genes 
that encode proteins of the sarcoglycan complex: α-, β-, γ-, and δ-sarcoglycans. These four 
sarcoglycans are components of a major dystrophin-glycoprotein complex that stabilizes 
the plasma membrane and cytoskeleton from the mechanical stress of contractile activity 
and is involved in signal transduction.1 The variants associated with the sarcoglycan gene 
characterize early childhood-onset progressive weakness that overlaps the spectrum as-
sociated with dystrophin variants in Duchenne and Becker muscular dystrophy with the 
relatively milder form LGMD.2,3 Since LGMD subtypes are difficult to distinguish based on 
clinical manifestations, muscle imaging, and laboratory tests such as immunoblotting, im-
munohistochemical analysis is used to determine the patterns of structural changes and 
protein deficiency. Subsequent molecular analysis is performed to identify specific genetic 
defects and the sites of chromosomal lesions. 
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CASE
This study reviewed two siblings diagnosed with LGMD2E 
with recessive inheritance patterns (Fig. 1A). The proband 
was a 43-year-old female (II-8) who showed delayed early 
motor milestones in crawling, sitting, and walking. She was 
the normal product of a full-term pregnancy, but at 8 years 
she showed a waddling gait and was never able to run. The 
patient used a wheelchair in her early teens due to the pro-
gression of foot deformity and motor difficulty. Her younger 
sibling was a 41-year-old female (II-9) who showed a slightly 
milder but otherwise similar clinical prognosis. She had 
reached her early developmental milestones as expected, 
but her mother reported that she had difficulty sitting up at 
4 years of age, with hypertrophy at the calves. The patient 
walked using a tiptoe gait as a result of shortening of the 
Achilles tendon, and exhibited a gradual loss of ambulation 
resulting in wheelchair dependency by the age of 17 years. 
Weakness of her upper limbs prevented her from raising her 
arms overhead after the third decade. 
Both siblings needed noninvasive ventilator support and 
were confined to bed due to diffuse and symmetric muscle 
weakness. Physical examination revealed ankle contrac-
ture, scapular winging, and diffuse muscular atrophy with 
significant weakness in both proximal and distal limbs. 
Bulbar muscles were not involved. Their serum creatine 
kinase (CK) levels were 184 and 254 IU/L (normal range: 
21–215 IU/L). Muscle biopsies were performed at the ages of 
34 and 32 years in the proband and her sister, respectively. 
Pathologic studies revealed similar chronic and myopathic 
features, including prominent fatty replacement with a few 
severe atrophic or reactive hypertrophic muscle fibers. Elec-
trocardiography and transthoracic echocardiography did 
not reveal any significant conduction or structural abnor-
malities, while electromyography findings were compatible 
with myopathy (Table 1). 
To identify the genetic cause of myopathy, we performed 
targeted sequencing of 212 myopathy-related genes, which 
identified a homozygous nonsense variant (c.601C>T;p.
Gln201Ter) in SGCB (Fig. 1B). This variant is classified as likely 
pathogenic based on the following evidence: 1) null variant 
in a gene where loss of function is a known disease mecha-
nism, 2) appearing at extremely low frequencies in controls, 
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deleterious gene-induced effects. This study was approved 
by the local institutional review board, and written informed 
consent was obtained from all patients.
DISCUSSION
Variants in sarcoglycan genes were reported recently,4 but 
the present report is the first to include clinical aspects of 
genetically confirmed cases with a likely pathogenic variant 
in SGCB in Korea. LGMD2E is a rare type of sarcoglycanopa-
thies that is associated with early-onset severe muscular dys-
trophy, myocardial involvement, and respiratory impairment 
developing as the disease progresses. In the present case, 
the age at onset ranged from neonatal to 4 years, with the 
early onset of disease followed by more-rapid loss of ambu-
lation. Both cases presented with the clinical characteristics 
of LGMDs: muscle weakness predominance in both axial and 
proximal muscles, progressing from the lower to the upper 
extremities and not encompassing diagnostic obstacles 
with other myopathies. Muscle biopsies revealed end-stage 
muscle atrophy, and the serum CK levels were not elevated, 
in proportion to the disease severity. Mechanical ventilation 
support was needed due to severe respiratory insufficiency 
following significant limb muscle weakness. All patients 
showed cognition preservation and no cardiac involvement 
even in the late stage of the disease, despite cases of cardio-
myopathy in LGMD2E frequently being reported.5
A
Fig. 1. Pedigree and sequencing chromatogram of the patients with limb-girdle muscular dystrophy. (A) The family pedigree: males (squares), females 
(circles), affected individuals (filled symbols), unaffected individuals (open symbols). The proband (II-8, black arrow) and the younger sibling (II-9, gray 
arrow) had a clinical presentation of childhood muscular dystrophy. (B) Sanger sequencing chromatogram of the SGCB variant in the proband. The 
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This case report has revealed a novel homozygous non-
sense variant at exon 4 in SGCB (c.601C>T;p.Gln201Ter). This 
variant was predicted to produce a truncated β-sarcoglycan 
caused by the lack of an extracellular portion including all 
glycosylation sites, and classified as likely pathogenic ac-
cording to the 2015 guidelines by the American College 
of Medical Genetics and Genomics and the Association for 
Molecular Pathology. It was not found in the ExAC or 1000G 
database as homozygotes, and so was anticipated to be dis-
ease-causing based on in-silico analyses implemented using 
VariantTaster (http://varianttaster.org). Truncating variants 
are known to be associated with a severe phenotype of LG-
MD2E.6 Nevertheless, a missense variant in exon 3 affecting 
proximal extracellular domain resulting in deficiency of all 
three sarcoglycans (α, β, and γ) tested immunohistochem-
ically can also cause a severe phenotype.7 The sarcoglycan 
expression and clinical presentation seem to be correlated, 
with the absence of sarcoglycans associated with a severe 
phenotype such as the early loss of ambulation. Likewise, 
variants in any single sarcoglycan gene can lead to the ab-
sence of this protein and a secondary deficiency of all sarco-
glycans. Since there is no specific immunostaining pattern 
for any sarcoglycanopathies,1 pathologic findings should 
be combined with the findings of muscle imaging, clinical 
presentation, and genetic analysis. Molecular genetics is a 
helpful tool for diagnosing muscular dystrophies, especially 
those with atypical clinical features.
Sarcoglycanopathies are known to be the third- to fourth-
most-common LGMD subtypes, whose relative frequencies 
vary with ethnicity and geographical distribution. However, 
their prevalence has been reported to be surprisingly low in 
Korea.4 LGMD2C is the most-common of the four sarcogly-
canopathies in India,8 while LGMD2D is the most prevalent 
in Europe and North America,2,9 and LGMD2E is the sec-
ond-most-common variant after LGMD2D in China.10 Fur-
ther research involving larger cohorts is needed to clarify the 
clinical and genetic spectrums with genotype–phenotype 
correlations of sarcoglycanopathies.
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